International journal of antimicrobial agents · 2025
Piperacillin/tazobactam clearance predicted by non-creatinine based estimates of GFR in critically ill adults.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barreto Erin F, Chang Jack, Rule Andrew D, Cole Kristin C, Fogelson Lindsay, Paul Johar, Jannetto Paul J, Athreya Arjun P, Scheetz Marc H, BLOOM Study Group
Аннотация
BACKGROUND AND OBJECTIVE: As a renally-eliminated beta-lactam antibiotic, estimated glomerular filtration rate (eGFR) is a central component of piperacillin/tazobactam pharmacokinetics. This study aimed to determine the optimal eGFR equation for inclusion in population pharmacokinetic models for piperacillin and tazobactam among critically ill adults.
METHODS: The study included critically ill adults treated with piperacillin/tazobactam at a single academic medical center between 2018 and 2022. Excluded individuals had acute kidney injury, received kidney replacement therapy, or had extracorporeal membrane oxygenation at piperacillin/tazobactam initiation. Non-linear mixed effects population pharmacokinetic models using eGFR equations with creatinine, cystatin C, or both were developed and compared.
RESULTS: Using 377 samples from 120 critically ill patients, we found that a two-compartment model with first-order elimination best fit the piperacillin data and a one-compartment model with first-order elimination best fit the tazobactam data. For piperacillin, the final population mean parameters (standard error) were 8.36 (0.55) L/h for CL and 12.96 (1.17) L for V1. The values for Q and V2 were fixed at 0.98 L/h and 18 L, respectively, due to low interindividual variation in these parameters. For tazobactam, the final population mean parameters were 8.12 (0.52) L/h for CL and 16.87 (1.44) L for V. Both final models identified eGFRcystatinC expressed in mL/min as the eGFR equation that best predicted drug clearance as a covariate.
CONCLUSIONS: An eGFR equation that includes cystatin C improves the predictive performance of pharmacokinetic models for piperacillin/tazobactam in critically ill adults.
METHODS: The study included critically ill adults treated with piperacillin/tazobactam at a single academic medical center between 2018 and 2022. Excluded individuals had acute kidney injury, received kidney replacement therapy, or had extracorporeal membrane oxygenation at piperacillin/tazobactam initiation. Non-linear mixed effects population pharmacokinetic models using eGFR equations with creatinine, cystatin C, or both were developed and compared.
RESULTS: Using 377 samples from 120 critically ill patients, we found that a two-compartment model with first-order elimination best fit the piperacillin data and a one-compartment model with first-order elimination best fit the tazobactam data. For piperacillin, the final population mean parameters (standard error) were 8.36 (0.55) L/h for CL and 12.96 (1.17) L for V1. The values for Q and V2 were fixed at 0.98 L/h and 18 L, respectively, due to low interindividual variation in these parameters. For tazobactam, the final population mean parameters were 8.12 (0.52) L/h for CL and 16.87 (1.44) L for V. Both final models identified eGFRcystatinC expressed in mL/min as the eGFR equation that best predicted drug clearance as a covariate.
CONCLUSIONS: An eGFR equation that includes cystatin C improves the predictive performance of pharmacokinetic models for piperacillin/tazobactam in critically ill adults.